Related Experiment Video
Updated: Sep 2, 2025
05:50
Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
Published on: June 2, 2023
1.3K
Low-Dose NSAIDs Efficacy in Orthopedic Applications
Francesco Oliva1,2, Marco Quaranta1,2, Lucio Cipollaro1,2
1Department of Musculoskeletal Disorders, Faculty of Medicine and Surgery.
Sports Medicine and Arthroscopy Review
|August 3, 2022
Summary
Low-dose non-steroidal anti-inflammatory drugs (NSAIDs) offer a safer alternative for musculoskeletal conditions, minimizing side effects in elderly patients while maintaining effectiveness. This study confirms their efficacy and safety profile.
Area of Science:
- Pharmacology
- Rheumatology
- Geriatrics
Background:
- Non-steroidal anti-inflammatory drugs (NSAIDs) and COXIBs carry risks, particularly severe adverse events in elderly individuals.
- Standard NSAID dosages are linked to higher risks compared to lower doses.
Purpose of the Study:
- To evaluate the effectiveness and safety of low-dose NSAIDs for musculoskeletal applications.
- To determine if reduced NSAID dosages can mitigate risks without compromising therapeutic benefits.
Main Methods:
- Systematic review of clinical trials and observational studies.
- Analysis of safety and efficacy data for low-dose NSAID use in musculoskeletal conditions.
- Comparison of low-dose NSAIDs against standard doses and placebo.
Main Results:
- Low-dose NSAIDs demonstrated significant efficacy in managing musculoskeletal pain and inflammation.
- Adverse event rates were notably lower in patients using low-dose NSAIDs compared to standard doses.
- No life-threatening issues were reported with low-dose NSAID use in the evaluated studies.
Conclusions:
- Low-dose NSAIDs represent a favorable risk-benefit profile for treating musculoskeletal disorders, especially in the elderly.
- Utilizing the lowest effective NSAID dose is recommended to enhance patient safety.
- Further research should focus on long-term outcomes of low-dose NSAID therapy.
Related Concept Videos
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
582
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
582
01:29Drugs for Treatment of Ulcerative Colitis in IBD
229
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
229
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
867
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
867
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
197
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
197
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
497
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
497